Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic
microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is …

Genomic and chromosomal instability are hallmarks of cancer and shape the genomic
composition of cancer cells, thereby determining their behavior and response to treatment …

The immunotherapeutic treatment of various cancers with an increasing number of immune
checkpoint inhibitors (ICIs) has profoundly improved the clinical management of advanced …

Close proximity between cytotoxic T lymphocytes and tumour cells is required for effective
immunotherapy. However, what controls the spatial distribution of T cells in the tumour …

Mismatch repair (MMR)-deficient cancer evolves through the stepwise erosion of coding
homopolymers in target genes. Curiously, the MMR genes MutS homolog 6 (MSH6) and …

Genomic and mitochondrial DNA molecules are exposed continuously for a damaging
activity of chemical, physical, and internal genotoxicants. When DNA repair machinery is not …

DNA damage repair deficiency leads to the increased risk of genome instability and
oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer …

Breast and ovarian cancers are some of the most common tumors in females, and the
genetic predisposition is emerging as one of the key risk factors in the development of these …